Theralase(R) 获得加拿大癌症疫苗专利。 Theralase(R) Granted Canadian Cancer Vaccine Patent.

Theralase Technologies 从加拿大知识产权局获得了癌症疫苗专利。 Theralase Technologies receives a patent for a cancer vaccine from the Canadian Intellectual Property Office. 该疫苗专为特定癌症治疗而设计，预计将于 2026 年进行针对膀胱癌的 II 期注册临床研究，并于 2024 年进行针对脑癌和肺癌的 Ib 期研究，目前正在等待毒理学结果。 The vaccine, designed for specific cancer treatment, is set to undergo Phase II registration clinical study for bladder cancer in 2026 and a Phase Ib study for brain and lung cancer in 2024, pending toxicology results. 该专利有助于探索治疗白血病、淋巴瘤和骨髓瘤等“液体癌症”的方法。 The patent enables exploration of treatment for "liquid cancers" like leukemia, lymphoma, and myeloma.